The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

被引：1
|
作者：
Grega, Dominik [1 ,2 ]
Kolar, Jozef [1 ]
机构：
[1] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Brno, Czech Republic
[2] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Palackeho Tr 1946-1, Brno 61242, Czech Republic
来源：
VALUE IN HEALTH REGIONAL ISSUES | 2024年 / 40卷
关键词：
direct costs; elasticity factor; friction period; indirect costs; loss of productivity; FRICTION-COST METHOD; QUALITY-OF-LIFE; PRODUCTIVITY; DISABILITY; ILLNESS; IMPACT; WORK;
D O I：
10.1016/j.vhri.2023.10.001
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [41] The Role of the Standard Basic Anti-Rheumatic Drugs and the Genetically Engineered Biological Drugs in The Treatment of Rheumatoid Arthritis
    Daria, Gerasimova
    Helen, Gerasimova
    Olga, Pashanova
    Lubov, Kondratyeva
    Tatiana, Panafidina
    Tatiana, Popkova
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : S37 - S38
  • [42] The burden of rheumatoid arthritis
    Wolfe, F
    AMERICAN JOURNAL OF MANAGED CARE, 1999, 5 (14): : S852 - S859
  • [43] The burden of rheumatoid arthritis and access to treatment:: determinants of access
    Lundqvist, J.
    Kastaeng, F.
    Kobelt, G.
    Joensson, B.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 8 (Suppl 2): : S87 - S93
  • [44] The burden of rheumatoid arthritis and access to treatment: a medical overview
    J. Smolen
    D. Aletaha
    The European Journal of Health Economics, 2008, 8 : 39 - 47
  • [45] The burden of rheumatoid arthritis and access to treatment: determinants of access
    J. Lundqvist
    F. Kastäng
    G. Kobelt
    B. Jönsson
    The European Journal of Health Economics, 2008, 8 : 87 - 93
  • [46] The burden of rheumatoid arthritis and access to treatment: a medical overview
    Smolen, J.
    Aletaha, D.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 8 (Suppl 2): : S39 - S47
  • [47] Biological modifier therapy for the treatment of rheumatoid arthritis
    Jenkins, JK
    Hardy, KJ
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2002, 323 (04): : 197 - 205
  • [48] Biological treatment in rheumatoid arthritis: when to stop?
    Kirwan, John R.
    Boers, Maarten
    LANCET, 2014, 383 (9914): : 288 - 289
  • [49] Role of biological agents in treatment of rheumatoid arthritis
    Law, Shing T.
    Taylor, Peter C.
    PHARMACOLOGICAL RESEARCH, 2019, 150
  • [50] Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan
    Ikeda, Kei
    Kaneko, Yuko
    Tsujita, Yuki
    Kawaguchi, Isao
    Patel, Jayeshkumar
    Yamazaki, Toru
    Fang, Siran
    Kawahito, Yutaka
    MODERN RHEUMATOLOGY, 2023, 34 (05) : 910 - 917
12345